Novartis announced on 1 September 2026 that its experimental oral drug remibrutinib produced promising results in late-stage clinical trials for the treatment of multiple sclerosis (MS). The company described the findings as positive in key studies.
Remibrutinib is being developed as an oral therapy for people with MS and the outcome was presented by Novartis as a success in the drug’s pivotal trials.
The company’s brief report focused on the favourable trial verdicts; detailed efficacy and safety data were not included in the initial announcement. #Novartis #remibrutinib #MultipleSclerosis #MS #FiatNews
Remibrutinib is being developed as an oral therapy for people with MS and the outcome was presented by Novartis as a success in the drug’s pivotal trials.
The company’s brief report focused on the favourable trial verdicts; detailed efficacy and safety data were not included in the initial announcement. #Novartis #remibrutinib #MultipleSclerosis #MS #FiatNews